FR07C0051I1 - - Google Patents

Info

Publication number
FR07C0051I1
FR07C0051I1 FR07C0051C FR07C0051I1 FR 07C0051 I1 FR07C0051 I1 FR 07C0051I1 FR 07C0051 C FR07C0051 C FR 07C0051C FR 07C0051 I1 FR07C0051 I1 FR 07C0051I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27495518&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR07C0051(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of FR07C0051I1 publication Critical patent/FR07C0051I1/fr
Application granted granted Critical
Publication of FR07C0051I2 publication Critical patent/FR07C0051I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
FR07C0051C 1999-07-02 2007-10-19 Dérivés de l' Erythropoietine Active FR07C0051I2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14225499P 1999-07-02 1999-07-02
US15022599P 1999-08-23 1999-08-23
US15154899P 1999-08-31 1999-08-31
US16615199P 1999-11-17 1999-11-17

Publications (2)

Publication Number Publication Date
FR07C0051I1 true FR07C0051I1 (enExample) 2007-12-14
FR07C0051I2 FR07C0051I2 (fr) 2008-05-09

Family

ID=27495518

Family Applications (2)

Application Number Title Priority Date Filing Date
FR0008609A Expired - Lifetime FR2795734B1 (fr) 1999-07-02 2000-07-03 Conjugues d'erythropoietine,compositons les comprenant et procede pour leur preparation
FR07C0051C Active FR07C0051I2 (fr) 1999-07-02 2007-10-19 Dérivés de l' Erythropoietine

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FR0008609A Expired - Lifetime FR2795734B1 (fr) 1999-07-02 2000-07-03 Conjugues d'erythropoietine,compositons les comprenant et procede pour leur preparation

Country Status (51)

Country Link
US (2) US6583272B1 (enExample)
EP (2) EP1839676A3 (enExample)
JP (2) JP3727009B2 (enExample)
KR (1) KR100593143B1 (enExample)
CN (2) CN1184233C (enExample)
AR (2) AR024625A1 (enExample)
AT (1) ATE370748T1 (enExample)
AU (1) AU736067B2 (enExample)
BG (1) BG65449B1 (enExample)
BR (2) BRPI0002276B8 (enExample)
CA (1) CA2310536C (enExample)
CO (1) CO5190661A1 (enExample)
CY (2) CY1107719T1 (enExample)
CZ (1) CZ299516B6 (enExample)
DE (3) DE60036053T2 (enExample)
DK (1) DK1064951T3 (enExample)
DO (1) DOP2000000030A (enExample)
EA (1) EA003777B1 (enExample)
ES (2) ES2289985T3 (enExample)
FR (2) FR2795734B1 (enExample)
GB (2) GB2353281B (enExample)
GC (1) GC0000197A (enExample)
GE (1) GEP20022804B (enExample)
GT (1) GT200000109A (enExample)
HR (1) HRP20000436B1 (enExample)
HU (1) HU226233B1 (enExample)
ID (1) ID26447A (enExample)
IL (1) IL137056A0 (enExample)
IS (1) IS2492B (enExample)
IT (1) IT1318606B1 (enExample)
LU (1) LU91363I2 (enExample)
MA (1) MA26746A1 (enExample)
MX (1) MXPA00006547A (enExample)
MY (1) MY128500A (enExample)
NL (1) NL300289I9 (enExample)
NO (2) NO327043B1 (enExample)
NZ (1) NZ505454A (enExample)
OA (1) OA11442A (enExample)
PA (1) PA8497801A1 (enExample)
PE (1) PE20010297A1 (enExample)
PL (1) PL202758B1 (enExample)
PT (1) PT1064951E (enExample)
RS (1) RS49928B (enExample)
SG (1) SG92717A1 (enExample)
SI (1) SI1064951T1 (enExample)
SK (1) SK286301B6 (enExample)
SV (1) SV2002000120A (enExample)
TN (1) TNSN00147A1 (enExample)
TR (1) TR200001956A2 (enExample)
TW (1) TWI235667B (enExample)
UY (1) UY26228A1 (enExample)

Families Citing this family (231)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2221717T3 (es) 1997-12-08 2005-01-01 Emd Lexigen Research Center Corp. Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general.
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
ES2267263T3 (es) * 1998-04-15 2007-03-01 Emd Lexigen Research Center Corp. Coadministracion de un inhibidor de la angiogenesis para reforzar la respuesta inmunologica por medio de la mediacion de una proteina de fusion de una citoquina con un anticuerpo.
US7304150B1 (en) * 1998-10-23 2007-12-04 Amgen Inc. Methods and compositions for the prevention and treatment of anemia
US7345019B1 (en) * 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
CZ299516B6 (cs) * 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US6617135B1 (en) * 1999-08-09 2003-09-09 Emd Lexigen Research Center Corp. Multiple cytokine protein complexes
CA2391080A1 (en) 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Erythropoietin forms with improved properties
US20050202538A1 (en) * 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
DK1252192T3 (da) * 2000-02-11 2006-11-20 Merck Patent Gmbh Forbedring af antistofbaserede fusionsproteiners serumhalveringstid
US6586398B1 (en) * 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
ATE291436T2 (de) * 2000-05-15 2005-04-15 Hoffmann La Roche Flüssige arzneizubereitung enthaltend ein erythropoietin derivat
RU2272644C2 (ru) * 2000-06-29 2006-03-27 Мерк Патент Гмбх Усиление иммунной реакции, медиатором которой является слитый протеин антитело-цитокин, при помощи комбинированного лечения агентами, увеличивающими поглощение иммуноцитокина
US20040082765A1 (en) * 2000-10-16 2004-04-29 Teruo Nakamura Peg-modified erythropoietin
MXPA03005406A (es) * 2000-12-20 2003-09-25 Hoffmann La Roche Conjugados de eritropoyetina.
EP1345628B1 (en) * 2000-12-20 2011-04-13 F. Hoffmann-La Roche AG Conjugates of erythropoietin (epo) with polyethylene glycol (peg)
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
EP1234583A1 (en) * 2001-02-23 2002-08-28 F. Hoffmann-La Roche Ag PEG-conjugates of HGF-NK4
KR100900176B1 (ko) * 2001-03-07 2009-06-02 메르크 파텐트 게엠베하 하이브리드 이소타입 항체 부분구조를 포함하는 단백질을위한 발현 기술
DE10112825A1 (de) 2001-03-16 2002-10-02 Fresenius Kabi De Gmbh HESylierung von Wirkstoffen in wässriger Lösung
US6992174B2 (en) * 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
CA2446087C (en) 2001-05-03 2013-06-18 Stephen D. Gillies Recombinant tumor specific antibody and use thereof
US6818613B2 (en) 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
KR100467751B1 (ko) 2001-12-03 2005-01-24 씨제이 주식회사 생체내 에리스로포이에틴 활성이 증진된 융합단백질
BR0214650A (pt) * 2001-12-04 2005-05-03 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
CN102526044A (zh) * 2001-12-06 2012-07-04 法布罗根股份有限公司 提高内源性红细胞生成素(epo)的方法
DE10209821A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
DE10209822A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
AU2003218045A1 (en) 2002-03-11 2003-09-29 Ortho Mcneil Pharmaceutical, Inc Methods for shp1 mediated neuroprotection
NZ537306A (en) * 2002-07-01 2008-11-28 Kenneth S Warren Inst Inc Compositions comprising mutein recombinant tissue protective cytokines having one or more amino acid substitutions facilitating transport of a molecule via transcytosis across an endothelial cell barrier
WO2004012773A1 (en) 2002-07-24 2004-02-12 F. Hoffmann-La Roche Ag Polyalkylene glycol acid additives
US7459435B2 (en) * 2002-08-29 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
US20050176627A1 (en) * 2002-09-09 2005-08-11 Anthony Cerami Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin
DE60332358D1 (de) * 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
RU2329274C2 (ru) * 2002-09-11 2008-07-20 Фрезениус Каби Дойчланд Гмбх Способ получения производных гидроксиалкилкрахмала
US7459436B2 (en) * 2002-11-22 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
US7388079B2 (en) * 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
JP4494977B2 (ja) * 2002-12-17 2010-06-30 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｇｄ２に結合するマウス１４．１８抗体のヒト化抗体（ｈ１４．１８）およびそのｉｌ−２融合タンパク質
US7553930B2 (en) 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
US20060104968A1 (en) * 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7610156B2 (en) 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
US7642340B2 (en) 2003-03-31 2010-01-05 Xencor, Inc. PEGylated TNF-α variant proteins
WO2004089421A2 (en) 2003-03-31 2004-10-21 Xencor, Inc Methods for rational pegylation of proteins
US7279174B2 (en) * 2003-05-08 2007-10-09 Advanced Cardiovascular Systems, Inc. Stent coatings comprising hydrophilic additives
MXPA05012314A (es) 2003-05-12 2006-04-18 Affymax Inc Radical separador para peptido modificado con polietilenglicol.
DK1625156T3 (da) * 2003-05-12 2013-01-07 Affymax Inc Peptider, der bindes til erythropoietinreceptoren
CA2525464A1 (en) * 2003-05-12 2004-11-25 Qun Yin Novel poly(ethylene glycol) modified compounds and uses thereof
PT1629007E (pt) * 2003-05-12 2009-05-06 Affymax Inc Péptidos novos que se ligam ao receptor da eritropoietina
EP1641481A4 (en) * 2003-05-30 2008-10-15 Centocor Inc TRAINING OF NEW ERYTHROPOIETIN CONJUGATES USING TRANSGLUTAMINASE
US7662607B2 (en) * 2003-07-30 2010-02-16 New Century Pharmaceuticals, Inc. Chalaropsis lysozyme protein and its method of use in anti-bacterial applications
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
EA010650B1 (ru) * 2003-09-29 2008-10-30 Уоррен Фармасьютикалз, Инк. Защищающие ткань цитокины для лечения и профилактики сепсиса и образования спаек
WO2005035564A2 (en) 2003-10-10 2005-04-21 Xencor, Inc. Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
JP2007514673A (ja) * 2003-12-19 2007-06-07 エフ．ホフマン−ラ　ロシュ　アーゲー 慢性炎症性腸疾患の際の鉄分布障害の処置におけるエリスロポエチンの使用
EP1548031A1 (en) * 2003-12-22 2005-06-29 Dubai Genetics FZ-LLC Nature-identical erythropoietin
WO2005063808A1 (en) * 2003-12-31 2005-07-14 Merck Patent Gmbh Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS
EP1756173B1 (en) * 2004-01-21 2019-04-03 Nektar Therapeutics Method of preparing propionic acid-terminated polymers
CN101001866A (zh) * 2004-02-02 2007-07-18 Ambrx公司 经修饰的人类干扰素多肽和其用途
CA2558738C (en) 2004-03-11 2013-02-05 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination
US7588745B2 (en) * 2004-04-13 2009-09-15 Si Options, Llc Silicon-containing products
US7253650B2 (en) 2004-05-25 2007-08-07 International Business Machines Corporation Increase productivity at wafer test using probe retest data analysis
WO2006062685A2 (en) * 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
JP2008519858A (ja) * 2004-11-11 2008-06-12 アフィーマックス・インコーポレイテッド エリスロポエチンレセプターに結合する新規ペプチド
CN103172747A (zh) 2005-01-25 2013-06-26 细胞治疗学公司 体内半衰期改变的生物活性蛋白质偶联物
WO2006089228A2 (en) * 2005-02-16 2006-08-24 Nektar Therapeutics Al, Corporation Conjugates of an epo moiety and a polymer
US8324159B2 (en) * 2005-06-03 2012-12-04 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7550433B2 (en) * 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7919461B2 (en) 2005-06-03 2011-04-05 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US20070072795A1 (en) * 2005-09-28 2007-03-29 Anton Haselbeck Treatment of neurodegenerative disorders
DE602006018969D1 (de) * 2005-10-04 2011-01-27 Bristol Myers Squibb Co Herstellung und reinigung von il-29
US8124095B2 (en) * 2005-10-07 2012-02-28 Armagen Technologies, Inc. Fusion proteins for delivery of erythropoietin to the CNS
US8142781B2 (en) * 2005-10-07 2012-03-27 Armagen Technologies, Inc. Fusion proteins for blood-brain barrier delivery
US8741260B2 (en) * 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
US20080171696A1 (en) * 2005-10-21 2008-07-17 Avigenics, Inc. Pharmacodynamically enhanced therapeutic proteins
US20070092486A1 (en) * 2005-10-21 2007-04-26 Avigenics, Inc. Glycolated and glycosylated poultry derived therapeutic proteins
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
ES2657628T3 (es) 2006-02-28 2018-03-06 Kodiak Sciences Inc. Conjugados poliméricos que contienen acriloiloxietilfosforilcolina y su preparación
WO2007108505A1 (ja) 2006-03-22 2007-09-27 Chugai Seiyaku Kabushiki Kaisha エリスロポエチン溶液製剤
SI2054074T1 (sl) * 2006-08-04 2014-12-31 Prolong Pharmaceuticals Llc Modificiran eritropoetin
US8497246B2 (en) * 2006-08-18 2013-07-30 Armagen Technologies, Inc. Methods for diagnosing and treating CNS disorders by trans-blood-brain barrier delivery of protein compositions
KR101248252B1 (ko) * 2006-11-28 2013-03-27 한올바이오파마주식회사 변형된 에리스로포이에틴 폴리펩티드와 이의 치료용 용도
MX2009008104A (es) * 2007-02-02 2009-08-07 Amgen Inc Hepcidina, antagonistas de hepcidina y metodos de uso.
US20090011040A1 (en) * 2007-05-02 2009-01-08 Naash Muna I Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
AR067537A1 (es) * 2007-07-17 2009-10-14 Hoffmann La Roche Purificacion de polipeptidos pegilados
AR067536A1 (es) * 2007-07-17 2009-10-14 Hoffmann La Roche Metodo para obtener una eritropoyetina mono-pegilada en una forma sustancialmente homogenea
JP5901877B2 (ja) 2007-07-27 2016-04-13 アーメイゲン・テクノロジーズ・インコーポレイテッドＡｒｍａｇｅｎ Ｔｅｃｈｎｏｌｏｇｉｅｓ， Ｉｎｃ． 中枢神経系のα−Ｌ−イデュロニダーゼ活性を増加させるための方法および組成物
WO2009043049A2 (en) * 2007-09-27 2009-04-02 Amgen Inc. Pharmaceutical formulations
WO2009064838A1 (en) 2007-11-15 2009-05-22 Amgen, Inc. Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration
US8101706B2 (en) 2008-01-11 2012-01-24 Serina Therapeutics, Inc. Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
EP3042922B1 (en) 2008-01-11 2017-07-19 Serina Therapeutics, Inc. Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
CA2711826C (en) 2008-01-25 2018-02-27 Amgen Inc. Ferroportin antibodies and methods of use
US9938333B2 (en) 2008-02-08 2018-04-10 Ambrx, Inc. Modified leptin polypeptides and their uses
TWI395593B (zh) 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
NZ601248A (en) 2008-04-14 2014-06-27 Halozyme Inc Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
US9315577B2 (en) 2008-05-01 2016-04-19 Amgen Inc. Anti-hepcidin antibodies and methods of use
EP3412300A1 (en) 2008-06-27 2018-12-12 Duke University Therapeutic agents comprising elastin-like peptides
US8278418B2 (en) 2008-09-26 2012-10-02 Ambrx, Inc. Modified animal erythropoietin polypeptides and their uses
US8318167B2 (en) 2008-11-13 2012-11-27 The General Hospital Corporation Methods and compositions for regulating iron homeostasis by modulation of BMP-6
EA036569B1 (ru) 2008-12-09 2020-11-24 Галозим, Инк. Способ получения полипептида гиалуронидазы ph20
US9533055B2 (en) 2009-03-18 2017-01-03 Armagen Technologies, Inc. Compositions and methods for blood-brain barrier delivery of IgG-decoy receptor fusion proteins
US9289699B2 (en) 2009-07-30 2016-03-22 Hoffmann-La Roche Inc. Moveable chromatography column separator
WO2011024025A1 (en) * 2009-08-28 2011-03-03 Avesthagen Limited An erythropoietin analogue and a method thereof
HRP20160530T1 (hr) 2009-09-17 2016-07-29 Baxalta Incorporated Stabilna ko-formulacija hijaluronidaze i imunoglobulina, te postupci njezine uporabe
UA107678C2 (uk) * 2009-09-23 2015-02-10 ратіофарм ГмбХ Процес очищення рекомбінантного людського еритропоетину (епо), епо, очищений таким чином, та фармацевтична композиція, що містить його
ES2725200T3 (es) 2009-10-09 2019-09-20 Armagen Inc Métodos y composiciones para aumentar la actividad de iduronato 2-sulfatasa en el SNC
MX344382B (es) 2009-10-23 2016-12-14 Amgen Inc * Adaptador de vial y sistema.
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
AU2011247659B2 (en) 2010-04-27 2014-07-24 Scil Technology Gmbh Stable aqueous MIA/CD-RAP formulations
HUE026173T2 (en) 2010-06-07 2016-05-30 Amgen Inc pharmaceutical Pump
EP2595624B1 (en) 2010-07-20 2018-01-31 Halozyme, Inc. Methods of treatment or prevention of the adverse side-effects associated with administration of an anti-hyaluronan agent
JP5735650B2 (ja) 2010-09-14 2015-06-17 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｐｅｇ化エリスロポエチンを精製するための方法
WO2012104278A1 (en) 2011-02-02 2012-08-09 F. Hoffmann-La Roche Ag Chromatography column support
JP2014510045A (ja) 2011-02-08 2014-04-24 ハロザイム インコーポレイテッド ヒアルロナン分解酵素の組成物および脂質製剤ならびに良性前立腺肥大症の治療のためのその使用
AU2012236573B2 (en) 2011-03-31 2016-06-02 Amgen Inc. Vial adapter and system
TR201905991T4 (tr) 2011-04-20 2019-05-21 Amgen Inc Oto enjektör aparatı.
US20130011378A1 (en) 2011-06-17 2013-01-10 Tzung-Horng Yang Stable formulations of a hyaluronan-degrading enzyme
EP3045188B1 (en) 2011-10-14 2020-12-23 Amgen Inc. Injector and method of assembly
KR101828828B1 (ko) 2011-10-24 2018-03-29 할로자임, 아이엔씨 항-히알루로난 제제 치료를 위한 동반 진단 및 이의 사용 방법
EP4338797A3 (en) 2011-12-02 2024-06-12 Armagen, Inc. Methods and compositions for increasing arylsulfatase a activity in the cns
BR112014016195A2 (pt) 2011-12-30 2020-10-27 Halozyme, Inc. variantes de polipeptídio ph20, formulações e usos das mesmas
US9913822B2 (en) 2012-04-04 2018-03-13 Halozyme, Inc. Combination therapy with an anti-hyaluronan agent and therapeutic agent
CN102816227A (zh) * 2012-08-30 2012-12-12 深圳赛保尔生物药业有限公司 回收促红细胞生成素的方法
WO2014062856A1 (en) 2012-10-16 2014-04-24 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
EP2922590B1 (en) 2012-11-21 2020-02-05 Amgen Inc. Drug delivery device
TWI614041B (zh) 2013-03-15 2018-02-11 安美基公司 用於注射器之匣盒
KR102218494B1 (ko) 2013-03-15 2021-02-19 인트린식 라이프사이언시스, 엘엘씨 항-헵시딘 항체 및 그의 용도
SG11201507417RA (en) 2013-03-15 2015-10-29 Amgen Inc Body contour adaptable autoinjector device
US10092703B2 (en) 2013-03-15 2018-10-09 Amgen Inc. Drug cassette, autoinjector, and autoinjector system
EP2976117B1 (en) 2013-03-22 2020-12-30 Amgen Inc. Injector and method of assembly
TW201534726A (zh) 2013-07-03 2015-09-16 Halozyme Inc 熱穩定ｐｈ２０玻尿酸酶變異體及其用途
WO2015035342A2 (en) 2013-09-08 2015-03-12 Oligasis Llc Factor viii zwitterionic polymer conjugates
EP3957345B1 (en) 2013-10-24 2025-12-10 Amgen Inc. Drug delivery system with temperature-sensitive control
CA2920894C (en) 2013-10-24 2023-03-14 Amgen Inc. Injector and method of assembly
US10994112B2 (en) 2014-02-05 2021-05-04 Amgen Inc. Drug delivery system with electromagnetic field generator
MX388536B (es) 2014-05-07 2025-03-20 Amgen Inc Autoinyector con elementos reductores del shock.
CN106470717B (zh) 2014-06-03 2020-09-11 安姆根有限公司 药物递送系统和使用方法
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
HUE043847T2 (hu) 2014-08-28 2019-09-30 Halozyme Inc Hialuronán-lebontó enzimmel és egy immun checkpoint inhibitorral végzett kombinációs terápia
AU2015321462B2 (en) 2014-09-22 2020-04-30 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
CN108064282A (zh) 2014-10-14 2018-05-22 哈洛齐梅公司 腺苷脱氨酶-2(ada2)、其变体的组合物及使用其的方法
AU2015332557B2 (en) 2014-10-14 2020-05-14 Amgen Inc. Drug injection device with visual and audio indicators
JP6849590B2 (ja) 2014-10-17 2021-03-24 コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． ブチリルコリンエステラーゼ両性イオン性ポリマーコンジュゲート
ES2785311T3 (es) 2014-12-19 2020-10-06 Amgen Inc Dispositivo de administración de fármacos con botón móvil o campo de interfaz de usuario
EP3848072A1 (en) 2014-12-19 2021-07-14 Amgen Inc. Drug delivery device with proximity sensor
US10538589B2 (en) 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
CA3069716C (en) 2015-02-17 2021-11-09 Amgen Inc. Drug delivery device with vacuum assisted securement and/or feedback
EP3261690B1 (en) 2015-02-27 2021-12-15 Amgen Inc. Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
WO2017100501A1 (en) 2015-12-09 2017-06-15 Amgen Inc. Auto-injector with signaling cap
BR112018013407A2 (en) 2015-12-30 2018-12-18 Kodiak Sciences Inc. antibodies and conjugates thereof
US11154661B2 (en) 2016-01-06 2021-10-26 Amgen Inc. Auto-injector with signaling electronics
WO2017160799A1 (en) 2016-03-15 2017-09-21 Amgen Inc. Reducing probability of glass breakage in drug delivery devices
CN105820232B (zh) * 2016-04-08 2019-05-17 昂德生物药业有限公司 单修饰聚乙二醇重组人促红素的制备方法及其制品和应用
WO2017189089A1 (en) 2016-04-29 2017-11-02 Amgen Inc. Drug delivery device with messaging label
US11389588B2 (en) 2016-05-02 2022-07-19 Amgen Inc. Syringe adapter and guide for filling an on-body injector
AU2017263558B2 (en) 2016-05-13 2022-12-22 Amgen Inc. Vial sleeve assembly
EP3458988B1 (en) 2016-05-16 2023-10-18 Amgen Inc. Data encryption in medical devices with limited computational capability
WO2017209899A1 (en) 2016-06-03 2017-12-07 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
WO2018004842A1 (en) 2016-07-01 2018-01-04 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
WO2018011381A1 (en) 2016-07-15 2018-01-18 F. Hoffmann-La Roche Ag Method for purifying pegylated erythropoietin
US20190328965A1 (en) 2016-08-17 2019-10-31 Amgen Inc. Drug delivery device with placement detection
WO2018081234A1 (en) 2016-10-25 2018-05-03 Amgen Inc. On-body injector
JP2020503976A (ja) 2017-01-17 2020-02-06 アムジエン・インコーポレーテツド 注入デバイスならびに関連する使用および組立方法
MX2019009625A (es) 2017-02-17 2019-10-09 Amgen Inc Dispositivo de administracion de farmacos con trayectoria de flujo de fluido esteril y metodo relacionado de ensamblaje.
EP3582829A1 (en) 2017-02-17 2019-12-25 Amgen Inc. Insertion mechanism for drug delivery device
EP3592403B1 (en) 2017-03-06 2025-08-20 Amgen Inc. Drug delivery device with activation prevention feature
CA3052482A1 (en) 2017-03-07 2018-09-13 Amgen Inc. Needle insertion by overpressure
AU2018230486B2 (en) 2017-03-09 2023-05-11 Amgen Inc. Insertion mechanism for drug delivery device
EP3570871B1 (en) 2017-03-20 2020-11-18 H. Hoffnabb-La Roche Ag Method for in vitro glycoengineering of an erythropoiesis stimulating protein
CN118743804A (zh) 2017-03-28 2024-10-08 美国安进公司 柱塞杆和注射器组件系统以及方法
CA3066399A1 (en) 2017-06-08 2018-12-13 Amgen Inc. Torque driven drug delivery device
AU2018280054B2 (en) 2017-06-08 2023-07-13 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
AU2018288604B2 (en) 2017-06-22 2023-12-21 Amgen Inc. Device activation impact/shock reduction
JP7091373B2 (ja) 2017-06-22 2022-06-27 カタリスト・バイオサイエンシーズ・インコーポレイテッド 改変された膜型セリンプロテアーゼ１（ｍｔｓｐ－１）ポリペプチドおよび使用方法
MA49461A (fr) 2017-06-23 2020-04-29 Amgen Inc Dispositif électronique d'administration de médicament comprenant un bouchon activé par un ensemble commutateur
MA49562A (fr) 2017-07-14 2020-05-20 Amgen Inc Système d'insertion-rétractation d'aiguille présentant un système à ressort en double torsion
US11672733B2 (en) 2017-07-21 2023-06-13 Amgen Inc. Gas permeable sealing member for drug container and methods of assembly
JP2020528296A (ja) 2017-07-25 2020-09-24 アムジエン・インコーポレーテツド ギヤモジュールを有する薬物送達デバイス及び関連する組立方法
US11484648B2 (en) 2017-07-25 2022-11-01 Amgen Inc. Drug delivery device with container access system and related method of assembly
WO2019032482A2 (en) 2017-08-09 2019-02-14 Amgen Inc. HYDRAULIC-PNEUMATIC PRESSURE CHAMBER DELIVERY SYSTEM
WO2019036181A1 (en) 2017-08-18 2019-02-21 Amgen Inc. BODY INJECTOR WITH STERILE ADHESIVE PATCH
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
ES2939292T3 (es) 2017-10-04 2023-04-20 Amgen Inc Adaptador de flujo para dispositivo de administración de fármacos
EP4257164A3 (en) 2017-10-06 2024-01-17 Amgen Inc. Drug delivery device with interlock assembly and related method of assembly
EP3694578B1 (en) 2017-10-09 2025-09-24 Amgen Inc. Drug delivery device with drive assembly and related method of assembly
MA50528A (fr) 2017-11-03 2020-09-09 Amgen Inc Systèmes et approches pour stériliser un dispositif d'administration de médicament
US12053618B2 (en) 2017-11-06 2024-08-06 Amgen Inc. Fill-finish assemblies and related methods
WO2019089178A1 (en) 2017-11-06 2019-05-09 Amgen Inc. Drug delivery device with placement and flow sensing
IL319987A (en) 2017-11-10 2025-06-01 Amgen Inc Plungers for drug delivery devices
JP7747438B2 (ja) 2017-11-16 2025-10-01 アムジエン・インコーポレーテツド 失速及び終点検出を有するオートインジェクタ
SG11202003004RA (en) 2017-11-16 2020-04-29 Amgen Inc Door latch mechanism for drug delivery device
CN111741770A (zh) 2017-12-29 2020-10-02 豪夫迈·罗氏有限公司 用于提供聚乙二醇化蛋白质组合物的方法
HRP20220041T1 (hr) 2017-12-29 2022-04-15 F. Hoffmann - La Roche Ag Postupak za dobivanje pegiliranog proteinskog pripravka
CN111727063A (zh) 2017-12-29 2020-09-29 豪夫迈·罗氏有限公司 用于提供聚乙二醇化蛋白质组合物的方法
SG11202008242XA (en) 2018-03-02 2020-09-29 Kodiak Sciences Inc Il-6 antibodies and fusion constructs and conjugates thereof
US20190351031A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
US12042645B2 (en) 2018-07-24 2024-07-23 Amgen Inc. Delivery devices for administering drugs
MX2021000749A (es) 2018-07-24 2021-03-29 Amgen Inc Dispositivos de suministro para administrar farmacos.
US12115360B2 (en) 2018-07-24 2024-10-15 Amgen Inc. Hybrid drug delivery devices with grip portion
US12303677B2 (en) 2018-07-24 2025-05-20 Amgen Inc. Hybrid drug delivery devices with optional grip portion and related method of preparation
EP3829692A1 (en) 2018-07-31 2021-06-09 Amgen Inc. Fluid path assembly for a drug delivery device
EP3613486B1 (de) * 2018-08-24 2020-10-07 UGA Biopharma GmbH Verfahren und anlage zur reinigung von epo und/oder einem epo-derivat
US20210346601A1 (en) 2018-09-24 2021-11-11 Amgen Inc. Interventional dosing systems and methods
EP3856283A1 (en) 2018-09-28 2021-08-04 Amgen Inc. Muscle wire escapement activation assembly for a drug delivery device
AU2019352616B2 (en) 2018-10-02 2024-10-10 Amgen Inc. Injection systems for drug delivery with internal force transmission
US12151089B2 (en) 2018-10-05 2024-11-26 Amgen Inc. Drug delivery device having dose indicator
JP2022504805A (ja) 2018-10-15 2022-01-13 アムジエン・インコーポレーテツド 薬物送達デバイスのプラットフォーム式組み立てプロセス
SG11202103800RA (en) 2018-10-15 2021-05-28 Amgen Inc Drug delivery device having damping mechanism
AU2019370159B2 (en) 2018-11-01 2025-05-29 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
US11213620B2 (en) 2018-11-01 2022-01-04 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
TWI831847B (zh) 2018-11-01 2024-02-11 美商安進公司 部分針頭縮回之藥物遞送裝置及其操作方法
PE20211664A1 (es) 2018-12-28 2021-08-26 Catalyst Biosciences Inc Polipeptidos de activador de plasminogeno, tipo urocinasa, modificados y metodos de uso
US11613744B2 (en) 2018-12-28 2023-03-28 Vertex Pharmaceuticals Incorporated Modified urokinase-type plasminogen activator polypeptides and methods of use
JP7510952B2 (ja) 2019-04-24 2024-07-04 アムジエン・インコーポレーテツド シリンジ滅菌確認アセンブリ及び方法
JP7608439B2 (ja) 2019-08-23 2025-01-06 アムジエン・インコーポレーテツド 構成可能な針シールド係合構成要素を備えた薬物送達デバイス及び関連方法
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
EP4219537A4 (en) 2020-09-22 2025-03-26 Jecho Laboratories, Inc. Glycosylation-modified erythropoietin and use thereof
WO2022159414A1 (en) 2021-01-22 2022-07-28 University Of Rochester Erythropoietin for gastroinfestinal dysfunction
CN117279929A (zh) 2021-05-10 2023-12-22 凯奥目生物科学株式会社 抗体组合物的纯化方法
CA3217207A1 (en) 2021-05-21 2022-11-24 Amgen Inc. Method of optimizing a filling recipe for a drug container
WO2023209074A1 (en) 2022-04-28 2023-11-02 Institut National de la Santé et de la Recherche Médicale Methods of restoring erythropoiesis in patients suffering from a sf3b1 mutant myelodysplastic syndrome by correcting coasy mis-splicing
EP4612312A1 (en) 2022-11-02 2025-09-10 F. Hoffmann-La Roche AG Method for producing glycoprotein compositions
CN116492448A (zh) * 2023-04-12 2023-07-28 深圳赛保尔生物药业有限公司 负载peg-epo及间充质干细胞的组合物、药物及其制备方法
WO2025227129A2 (en) 2024-04-25 2025-10-30 Starrock Pharma Llc Delivery vehicles comprising proglucagon derived polypeptides and anabolic polypeptides and uses thereof
WO2026030152A1 (en) 2024-07-29 2026-02-05 Amgen Inc. System and method for assessing transferability of a fill recipe

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
KR850004274A (ko) * 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
JPS6197229A (ja) 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US5641663A (en) * 1985-11-06 1997-06-24 Cangene Corporation Expression system for the secretion of bioactive human granulocyte macrophage colony stimulating factor (GM-CSF) and other heterologous proteins from steptomyces
US4902502A (en) 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5674534A (en) * 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
NZ250375A (en) 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
CN1057534C (zh) * 1993-08-17 2000-10-18 柯瑞英-艾格公司 促红细胞生成素类似物
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
ES2093593T1 (es) * 1995-05-05 1997-01-01 Hoffmann La Roche Proteinas obesas (ob) recombinantes.
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US6025324A (en) * 1996-05-15 2000-02-15 Hoffmann-La Roche Inc. Pegylated obese (ob) protein compositions
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
EP0902085B1 (en) * 1997-09-01 2003-12-03 Aventis Pharma Deutschland GmbH Recombinant human erythropoietin with advantageous glycosylation profile
AU2346900A (en) 1998-11-30 2000-06-19 Eli Lilly And Company Erythropoietic compounds
CZ299516B6 (cs) * 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
JO2291B1 (en) * 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythropoietin derivatives
WO2001068141A2 (en) 2000-03-17 2001-09-20 Maxygen Aps Dispersions of polypeptide conjugates
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
ATE291436T2 (de) * 2000-05-15 2005-04-15 Hoffmann La Roche Flüssige arzneizubereitung enthaltend ein erythropoietin derivat

Also Published As

Publication number Publication date
LU91363I2 (fr) 2007-11-12
KR20010049676A (ko) 2001-06-15
GB2393960B (en) 2004-08-04
NO2009010I2 (no) 2014-06-02
CA2310536C (en) 2007-09-11
CN1280137A (zh) 2001-01-17
GC0000197A (en) 2006-03-29
HUP0002553A2 (en) 2001-03-28
ES2289985T3 (es) 2008-02-16
ATE370748T1 (de) 2007-09-15
FR2795734B1 (fr) 2005-09-30
JP3727009B2 (ja) 2005-12-14
DE10031839A1 (de) 2001-02-01
DE60036053T2 (de) 2008-01-03
NO20003372D0 (no) 2000-06-28
GB2353281A (en) 2001-02-21
UY26228A1 (es) 2000-10-31
GB2393960C (en) 2012-08-29
NO2009010I1 (no) 2009-05-25
DK1064951T3 (da) 2007-10-08
KR100593143B1 (ko) 2006-06-26
AR055650A2 (es) 2007-08-29
HU0002553D0 (en) 2000-08-28
YU40700A (sh) 2003-12-31
BR0002276A (pt) 2001-12-11
EA200000607A1 (ru) 2001-02-26
NL300289I2 (nl) 2010-02-01
NZ505454A (en) 2001-12-21
AU4274400A (en) 2001-01-04
CN1184233C (zh) 2005-01-12
DE122007000064I1 (de) 2008-01-03
TNSN00147A1 (fr) 2005-11-10
CY2007021I1 (el) 2009-11-04
SV2002000120A (es) 2002-01-31
CZ20002386A3 (cs) 2002-04-17
MXPA00006547A (es) 2004-10-28
CY1107719T1 (el) 2010-07-28
HK1068354A1 (en) 2005-04-29
RS49928B (sr) 2008-09-29
PL341187A1 (en) 2001-01-15
EP1064951A3 (en) 2002-03-20
EP1064951A2 (en) 2001-01-03
BG65449B1 (bg) 2008-08-29
US20030120045A1 (en) 2003-06-26
FR07C0051I2 (fr) 2008-05-09
EP1839676A3 (en) 2008-09-03
GT200000109A (es) 2001-12-21
EA003777B1 (ru) 2003-08-28
GB2393960A (en) 2004-04-14
BG104570A (en) 2001-09-28
PL202758B1 (pl) 2009-07-31
JP2004155787A (ja) 2004-06-03
BRPI0002276B1 (pt) 2019-05-14
NO20003372L (no) 2001-01-03
AU736067B2 (en) 2001-07-26
HUP0002553A3 (en) 2005-11-28
JP2001064300A (ja) 2001-03-13
CO5190661A1 (es) 2002-08-29
FR2795734A1 (fr) 2001-01-05
PE20010297A1 (es) 2001-03-07
CN1283664C (zh) 2006-11-08
IS2492B (is) 2009-02-15
ID26447A (id) 2001-01-04
HU226233B1 (en) 2008-07-28
IT1318606B1 (it) 2003-08-27
PT1064951E (pt) 2007-09-10
BRPI0002276B8 (pt) 2021-05-25
TR200001956A2 (tr) 2001-01-22
IS5554A (is) 2001-01-02
ES2191511B1 (es) 2005-01-01
CA2310536A1 (en) 2001-01-02
HK1033328A1 (en) 2001-08-24
SG92717A1 (en) 2002-11-19
OA11442A (fr) 2004-04-28
EP1064951B1 (en) 2007-08-22
TWI235667B (en) 2005-07-11
NL300289I9 (nl) 2019-08-21
IL137056A0 (en) 2001-06-14
ITMI20001479A1 (it) 2001-12-30
ITMI20001479A0 (it) 2000-06-30
NO327043B1 (no) 2009-04-06
EP1839676A2 (en) 2007-10-03
MA26746A1 (fr) 2004-12-20
CZ299516B6 (cs) 2008-08-20
GB0016205D0 (en) 2000-08-23
PA8497801A1 (es) 2001-12-14
CY2007021I2 (el) 2009-11-04
US6583272B1 (en) 2003-06-24
SK286301B6 (en) 2008-07-07
CN1515590A (zh) 2004-07-28
SI1064951T1 (sl) 2007-12-31
GB2353281B (en) 2004-06-09
GB0400086D0 (en) 2004-02-04
SK9872000A3 (en) 2002-06-04
DOP2000000030A (es) 2002-07-15
ES2191511A1 (es) 2003-09-01
LU91363I9 (enExample) 2018-12-31
HRP20000436B1 (en) 2008-01-31
DE60036053D1 (de) 2007-10-04
NL300289I1 (nl) 2007-11-01
DE122007000064I2 (de) 2010-03-25
GEP20022804B (en) 2002-09-25
AR024625A1 (es) 2002-10-16
MY128500A (en) 2007-02-28
HRP20000436A2 (en) 2001-06-30

Similar Documents

Publication Publication Date Title
BE2018C020I2 (enExample)
BE2015C057I2 (enExample)
BE2016C007I2 (enExample)
BE2015C018I2 (enExample)
BE2014C017I2 (enExample)
BE2013C051I2 (enExample)
BE2013C020I2 (enExample)
BE2013C015I2 (enExample)
BE2013C001I2 (enExample)
BE2012C036I2 (enExample)
BE2008C046I2 (enExample)
BE1025464I2 (enExample)
BE2010C011I2 (enExample)
BRPI0017527B8 (enExample)
BE2008C047I2 (enExample)
BE2011C004I2 (enExample)
BRPI0001672A2 (enExample)
BRPI0001542A2 (enExample)
JP2002517269A5 (enExample)
BRPI0012675B8 (enExample)
BRPI0017522A2 (enExample)
BRPI0303609A (enExample)
BRMU7902607U2 (enExample)
BRPI9917761A2 (enExample)
ECSDI990560S (enExample)